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E-SELECTIN (CD62E) is an endothelial specific glycoprotein
belonging to the selectin family of adhesion molecules.
Because a high expression of this molecule at intestinal
mucosal surfaces in inflammatory bowel disease (IBD)
has been described earlier, the aim was to assess serum
levels of E-selectin (sE-selectin) and to correlate it to
disease activity, and further to evaluate its chemotactic
properties at physiological concentrations. Levels of sE-
selectinwere measuredby a sandwich ELISA technique in
31 IBD patients together with 15 healthy volunteers. In
ulcerative colitis the median value was 0.46 nM
(0.16-0.75), in Crohn’s disease 0.47 nM (0.22-1.24), and
in healthy controls 0.34 nM (0.22-0.83). No statistically
significant differences in sE-selectin were revealed be-
tween these groups (p > 0.05). The in vitro chemotactic
capabilities of E-selectin (in the concentration range of
0.10-31.4 nM) were assessed using the leading front tech-
nique. A significantly increased migratory response was
found at concentrations of 1.00 (p < 0.05) and 3.14 nM
(p < 0.02). It is concluded that sE-selectin in contrast to
sICAM-1 does not act as a sensitive indicator of local
immune activation in IBD. However, E-selectin may be
important for recruitment and accumulation of
neutrophilic granulocytes and other phagocytes involved
in the inflammatory process seen in IBD. Future investi-
gations are encouraged in order to reveal its in vivo
effects.
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Introduction
The pathogenesis of the inflammatory bowel dis-
eases (IBD), i.e. ulcerative colitis (UC) and Crohn’s
disease (CD), is not yet clarified. Among the media-
tors which in the view of recent research are thought
to be of importance for the pathogenesis of these
diseases are the adhesion molecules, and among
them E-selectin (CD62E) (previously named ELAM-1,
endothelial-leucocyte adhesion molecule-I) with a
molecular weight of 115 kDa.
The E-selectin molecule is normally not present on
the surfaces of vascular endothelial cells, but in vitro
investigations have revealed that stimulation with
certain cytokines (i.e. interleukin-1, tumour necrosis
factor-0t, lipopolysaccharides, substance P, and inter-
feron-g) induces production and expression of E-
selectin on surfaces of such cells. 1-7 The amount of E-
selectin increases shortly after stimulation with these
cytokines, whereas it decreases after stimulation for
16-24 h.4-7 On the contrary, stimulation with TNF-
continuously increases production of E-selectin.:
After epicutaneous provocation for 2 h in vivo with
chemicals known to be antigenic in susceptible pa-
tients, E-selectin is expressed on the luminal mem-
brane of the vascular endothelial cells. E-selectin
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amounts to a peak level in approximately 24 h, and
then decreases.
E-selectin mediates the binding between endo-
thelial cells, particularly to neutrophilic granulocytes
(PMNs), but also to basophilic and eosinophilic
granulocytes. It also mediates binding to mono-
cytes9’1 as well as to a sub-group ofT cells (CLA/) and
certain strains of tumour cells.9,1,12 E-selectin has a
chemotactic effect, and the activity of E-selectin in
vitro is crucial for the migration of granulocytes
across endothelial monolayers.9a3
E-selectin is detectable at the luminal membranes
of endothelial cells in active IBD but not in inactive
IBD or in healthy volunteers.4 Accordingly, electron
microscopy has shown E-selectin to be exocytosed
into the vascular lumen. 15 Therefore, it has been
suggested that E-selectin is both a transmembrane
protein and a secretory protein.
Antibodies to the E-selectin ligand, sLex, have been
shown to react with venous endothelia of the in-
flamed appendix,
16 and an analogous mechanism of
E-selectin directing leukocytes to inflamed bowel
segments may occur in IBD.
The aims of this study was to examine: (1) if
E-selectin was present in serum from IBD patients
and whether this concentration correlates to disease
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activity, and (2) the chemotactic properties of E-
selectin on PMNs.
Patients and methods
Patients.. Plasma from 31 consecutive patients with
well established IBD (16 with UC17 and 15 with CD18),
seen in the out-patient clinic, and 15 healthy volun-
teers, all aged 18-75 years, were studied for E-
selectin content using ELISA methods. None had
received glucocorticoids within the preceding 4
weeks, and none was colectomized. Patients with
known auto-immune diseases or other chronic in-
flammator conditions were excluded. Disease activ-
ity was scored according to Tvede et al.,9 modified
according to Langholz et aL and Munkholm et aL,
1
by the number of bowel movements per day, the
presence of blood, mucus and pus in the stools,
abdominal pain, and general symptoms such as
malaise, weight loss, fever, and symptoms from
joints, skin and eyes (Table 1). Essential clinical
parameters are given in Table 2. All patients apart
from six (three with UC and three with CD) were
treated with 5-aminosalicylic acid-containing drugs
(1-4 g/day). Blood from eight healthy volunteers
was obtained for purification of PMNs to be used in
a chemotactic assay.
ELISA: Serum E-selectin (sE-selectin) was analysed by
a sandwich enzyme linked immunoassay (ELISA)
(R&D Systems Europe Ltd, Abingdon, UK). In brief,
two E-selectin monoclonal antibodies, recognizing
different epitopes of the E-selectin molecule, were
precoated onto polystyrene microtitre wells. Stand-
Table 1. Criteria for determination of inflammatory bowel disease
(IBD) activity Symptoms
Symptoms IBD activity
Inactive Mild Moderate Severe
Bowel movements < 2 3-4 > 5 > 5
per day
Blood, mucus, pus* < Daily Daily Daily
Abdominal pain Mild Frequent
Extraintestinal Few Many
symptoms
Modified after Tvede et all9
Blood, mucus and pus are not characteristic symptoms in Crohn’s
disease, regardless of disease activity.
ards or diluted samples were then placed in the wells
followed immediately by addition of an enzyme
conjugated E-selectin monoclonal antibody. E-
selectins in serum or standards were bound to the
coating antibody, while the conjugated antibody was
bound to another distinct epitope on captured E-
selectin. A chromogen solution was added to the
wells forming a coloured end product, proportional
to the amount of E-selectin in the samples. A conju-
gate of streptavidin and horseradish peroxidase
(Streptavidin-HRP Conjugate, R&D Systems)was
used to catalyse this process. The concentration of
sE-selectin (nM) was measured by use of a standard
curve based on six known concentrations of
recombinant E-selectin and an ELISA reader at an
absorption of 450 nm (EAR 400, SLT Labinstruments,
Salzburg, Austria). Absorption at 630 nm was used
for reference. The detection limit was 8.7 pM, and the
coefficient of variation 0.5. According to the manu-
facturer, both monoclonal antibodies were raised
specifically against the E-selectin molecule.
Isolation ofneutrophils: Peripheral blood was drawn
in EDTA (0.2 M). Purification of PMNs was in all
cases initiated within 30 min after blood was drawn.
After a methylcellulose sedimentation of erythrocytes
and haemolysis, leukocytes were washed three times
and re-suspended in Gey-albumin solution (2%) at a
concentration of 2 x 106 cells/ml. The final cell sus-
pension contained approximately 80% PMNs, recov-
ery was 70%, and viability after chemotaxis more
than 95%.
Chemotaxis: E-selectin antigen (200 btg/ml) in PBS
(R&D Systems Europe Ltd), Gey’s solution, casein
(Hammersten, Merck, Darmstadt, Germany), and
millipore filters (3 btm pore size, thickness 140 l.tm in
dry condition) (Sartorius, 25N, type SMl1302,
G6ttingen, Germany) were used in the chemotactic
assay. E-selectin antigen was diluted with Gey’s sol-
ution into the following concentrations: 0.10, 0.31,
1.00, 3.14, 10.0, and 31.4 nM. Boyden chambers with
cell suspension and E-selectin suspension separated
by nitro-cellulose filters were incubated at 37C for
45 min. Median migratory responses were assessed
by the leading front technique, and were based on
the analysis of five randomly selected fields as de-
scribed previously in detail.2 To estimate spon-
Table 2. Clinical parameters of patients with chronic inflammatory bowel diseases
Subjects No. Age* Sex Disease activity
(years)
Inactive Mild Moderate Severe
Healthy controls 15 45 (36-60) 12F, 3M
Ulcerative colitis 16 37 (18-75) 11 F, 5M 5 4 5 2
Crohn’s disease 15 42 (22-63) 9F, 6M 2 2 6 5
216
*Medians are given with ranges in brackets.
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taneous migration (chemokinesis), control experi-
ments were carried out in which PMNs in Gey’s
solution migrated towards Gey’s solution alone
(negative control). All results of E-selectin
chemotaxis were corrected for chemokinesis. In ad-
dition, a positive control was assessed with PMNs in
Gey’s solution and compared with casein.
Ethics: Informed consent was obtained before blood
samples were drawn in accordance with the Second
Helsinki Declaration. The study was approved by the
Scientific Ethical Committee of Copenhagen County.
Statistics: Non-parametric statistics (medians and
ranges) and Mann-Whitney’s rank sum test were
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FIG. 2. Chemotactic effect of recombinant E-selectin on PMNs in healthy
volunteers given as migration in l.tm. Medians and 25/75 percentiles are
shown. For the concentration 31.4 nmol/I n 5, for the others n 8. The
migration ranged from -36.0 to 28.0 l.tm (at 0.10 nM E-selectin); from -18.0
to 36.5 lxm (0.31 nM); from -36.0 to 58.0 l.tm (1.00 nM); from 7.0 to 28.0 l.tm
(3.14 nM); from -12.0 to 27.0m (10.0 nM); and from -24.0 to 37.0 am
(31.4 nM).
Results
Serum E-selectin: The median serum concentration of
E-selectin was in UC 0.46 nM (0.16-0.75) (p > 0.05)
and in CD 0.47 nM (0.22-1.24) (p > 0.05) compared
with healthy volunteers 0.34 nM (0.22--0.83). Fig. 1
shows sE-selectin concentrations in IBD patients
with different disease stages. No correlation to dis-
ease activity was revealed (p > 0.05). An increase in
the concentration of serum E-selectin in IBD patients
could not be demonstrated after stratification for sex,
age, number of bowel movements per day, presence
of blood, mucus and pus in the stools, abdominal
pain and presence of extraintestinal symptoms.
Chemotaxis assays: The chemotactic effect of E-selec-
tin on peripheral PMNs expressed as the migration in
m/45min is shown in Fig. 2. Corrected for
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FIG. 1. Concentration of serum E-selectin (nM) among patients with chronic
inflammatory bowel diseases, divided on disease activities. The reference
range (15 healthy volunteers) is shown (shaded area). Ulcerative colitis (e)
and Crohn’s disease (O). The median values were 0.46 nM for inactive,
0.35 nM for mild, 0.53 nM for moderate, and 0.49 nM for severe UC; and
0.53 nM for inactive, 0.74 nM for mild, 0.37 nM for moderate, and 0.41 for
severe CD. The median value for controls was 0.34 nM.
58m in 45 min. Migration had a peak at an E-
selectin concentration of 1.00nM. A significantly
increased migratory response corrected for chemo-
kinesis was seen at 1.00 nM (p < 0.05) and 3.14 nM
(p< 0.02, Mann-Whitney’s test), whereas at other
concentrations no statistically significant differences
were detected.
With regard to the inter-assay variation, a negative
value of migration indicated that the spontaneous
migration and the E-selectin directed migratory re-
sponse were identical.
Discussion
E-selectin has previously been shown to be ex-
pressed on the surface of vascular endothelia in
a variety of pathological processes located with
other tissues, e.g. skin, liver, kidney, gingiva and
arteries.8,21-24 However, none of the included IBD
patients had such coexisting diseases.
The results suggest that the sE-selectin concentra-
tion is not increased in IBD, and it is therefore likely
that sE-selectin in itself is not sufficient to induce and
maintain the inflammatory response in IBD. How-
ever, it is possible that E-selectin is secreted into the
blood stream during acute phases of inflammation
and thereby may be involved in the accumulation of
PMNs at the inflamed intestinal areas in IBD.
The IBD patients included were allowed to con-
tinue 5-aminosalicylic acid treatment. However, the
sE-selectin concentrations in six patients not receiv-
ing 5-aminosalicylic acid (one with inactive UC, five
with moderate or severe IBD) ranged from 19.1 to
70.4 nM. These patients, however, did not influence
the overall results. Thus, it is unlikely that 5-amino-
salicylic, acid may influence E-selectin production.
Paraclinical parameters such as orosomucoid (0tl-
acid glycoprotein) and haemoglobin are included in
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the disease activity index described by Tvede et al.19
However, these criteria were not used in our study,
as the blood concentration of E-selectin was related
only to clinical parameters.
Because a correlation between sE-selectin and dis-
ease activity was lacking, sE-selectin cannot be used
as an activity marker in IBD. This in contrast to the
recent findings that slCAM-1 is significantly increased
in active IBD (355 ng/ml), compared with inactive IBD
(310 ng/ml) and controls (245 ng/ml) (p 0.00002). 25
Within the different activity stages, a considerable
inter-individual variation of E-selectin concentration
was found. Further, a large inter-individual variation
was seen in healthy volunteers, confirming observa-
tions by Fuggle et al. 22 in transplanted kidneys.
The chemotactic activity of PMNs in our assay was
elicited with physiological levels of E-selectin. The
concentrations of sE-selectin were in the range of
0.16 to 1.24 nM, and at these concentrations a
chemotactic effect on PMNs was found. The
chemotactic effect of recombinant E-selectin has pre-
viously been analysed by Lo et al. 26 at 10-1 000 nM,
showing maximum chemotactic effect at approxi-
mately 100nM. Lo et al. 26 did not find any
chemotactic effect at concentrations of E-selectin
below 10 nM. The present study has revealed such
an activity even at concentrations of 0.10 nM, and a
significant chemotactic effect was seen at 1 00 nM.
Probably, this is due to methodological differences
since larger pore size filters (3 l.tm) were used com-
pared with those used by Lo et al.26, who used 2 btm
pore sizes.
From both the present and other results,24 it is
evident that E-selectin by acting with the dual func-
tion of transmembrane receptor protein and circulat-
ing protein may direct PMNs to inflamed segments in
IBD.
Further research on adhesion molecules in IBD
patients must be carried out on patients without
other known diseases. To avoid a possible influence
of anti-inflammatory drugs, investigations should be
performed on newly diagnosed IBD patients before
initiation of specific anti-inflammatory treatment.
Additionally, in vivo studies of the ability of E-
selectin to direct leukocytes across the vascular
endothelial cell lining are needed.
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